GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Baxalta Inc (NYSE:BXLT) » Definitions » Owner Earnings per Share (TTM)

Baxalta (Baxalta) Owner Earnings per Share (TTM) : (As of Mar. 2016)


View and export this data going back to 2015. Start your Free Trial

What is Baxalta Owner Earnings per Share (TTM)?

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Baxalta does not have enough data to calculate Owner Earnings per Share (TTM), so as Price-to-Owner-Earnings ratio.


The historical rank and industry rank for Baxalta's Owner Earnings per Share (TTM) or its related term are showing as below:



BXLT's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 34.175
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

Baxalta's Earnings per Share (Diluted) for the three months ended in Mar. 2016 was $0.21. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2016 was $1.21. It's PE Ratio ratio for today is 38.10.

Baxalta's EPS without NRI for the three months ended in Mar. 2016 was $0.21. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2016 was $1.19. It's PE Ratio without NRI ratio for today is 38.67.


Baxalta Owner Earnings per Share (TTM) Historical Data

The historical data trend for Baxalta's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Baxalta Owner Earnings per Share (TTM) Chart

Baxalta Annual Data
Trend Dec12 Dec13 Dec14 Dec15
Owner Earnings per Share (TTM)
- - - -

Baxalta Quarterly Data
Dec12 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Baxalta's Owner Earnings per Share (TTM)

For the Biotechnology subindustry, Baxalta's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Baxalta's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Baxalta's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Baxalta's Price-to-Owner-Earnings falls into.



Baxalta Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

Baxalta does not have enough data to calculate Owner Earnings per Share (TTM). Please check Wal-Mart Stores Inc, as your reference.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


Baxalta Owner Earnings per Share (TTM) Related Terms

Thank you for viewing the detailed overview of Baxalta's Owner Earnings per Share (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


Baxalta (Baxalta) Business Description

Industry
Traded in Other Exchanges
N/A
Address
Baxalta Inc was incorporated on September 8, 2016. It is a biopharmaceutical company engaged in the field of unmet medical needs covering various diseases which includes haemophilia, immunology and oncology. The Company develops, manufactures and markets a diverse portfolio of treatments for hemophilia and other bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute medical conditions, as well as oncology treatments for acute lymphoblastic leukemia. It also invests in emerging technology platforms, including gene therapy and biosimilars. Its competitors include Advate, Feiba, Gammagard. The Company is subject to rules and regulations put forth by the jurisdiction it operates in.
Executives
Gail D Fosler director C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
John Glasspool officer: See Remarks C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Dagmar Rosa-bjorkeson officer: EVP and President, Biosimilars C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
David D. Meek officer: EVP and President, Oncology 3000 KENT AVENUE; SUITE A1-100, WEST LAFAYETTE IN 47906
Karen Jean Ferrante director 150 ADIRONDACK DRIVE, EAST GREENWICH RI 02818
Peter G Edwards officer: SVP and General Counsel C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Robert J. Hombach officer: EVP. CFO and COO C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Blake E Devitt director C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Wayne T Hockmeyer director ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Anne-marie Law officer: EVP & Head of Human Resources C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Stroucken Albert P L director BAXTER INTERNATIONAL INC., ONE BAXTER PARKWAY, DEERFIELD IL 60015
Gavin James R Iii director BAXTER INTERNATIONAL INC, ONE BAXTER PARKWAY, DEERFIELD IL 60015
John D Forsyth director C/O BAXTER INTERNATIONAL, ONE BAXTER PARKWAY, DEERFIELD IL 60015
Ludwig Hantson director, officer: President and CEO C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510
Francois Nader director 550 HILLS DRIVE, BEDMINSTER NJ 07921

Baxalta (Baxalta) Headlines

From GuruFocus

Third Avenue Management Comments on Baxalta

By Holly LaFon Holly LaFon 03-29-2016

Daniel Loeb Comments on Seven & i Holdings

By Holly LaFon 11-03-2015

Tweedy Browne Fund 4th Quarter Commentary

By Holly LaFon Holly LaFon 01-27-2016

Keeley Funds Comments on Baxalta Inc.

By Holly LaFon Holly LaFon 02-03-2016

Is Baxalta a Good Spin-Off Opportunity?

By Raman Minhas Raman Minhas 10-15-2015

Third Avenue Management Comments on Baxalta

By Holly LaFon Holly LaFon 12-10-2015

Undervalued Baxalta Shares Target of Acquisition by Shire Plc

By Ben Reynolds Ben Reynolds 08-05-2015

Third Avenue Buys Baxter Spin-Off

By Kyle Ferguson Kyle Ferguson 01-17-2016

Jeff Auxier Sells Precision Castparts, AT&T, Microsoft

By Tiziano Frateschi Tiziano Frateschi 06-23-2016

Baxalta Vs. AbbVie: Biopharma Spin-Off Battle

By Ben Reynolds Ben Reynolds 08-20-2015